On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Merus N.V. (NASDAQ:MRUS) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN). Here’s what you need to know. What To Know: ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Incyte will make additional $80M investment in new partner and pay up to $350M milestones per program Incyte and Merus have signed a global strategic collaboration focused on the discovery and ...

Caris to provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.

Merus (NASDAQ:MRUS) has observed the following analyst ratings within the last quarter: In the last 3 months, 19 analysts have offered 12-month price targets for Merus. The company has an average ...

A targeted cancer therapy from Merus has early clinical trial results suggesting it can treat tumors characterized by a genetic signature that hasn’t been addressed before, and the biotech is eying ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...